SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Valliere who wrote (336)10/5/1997 8:50:00 PM
From: sam   of 834
 
I think I adressed your first three questions in my last message (if not, let me know and I'll do so more thoroughly). As for number 4, all I keep hearing (and Wand states in her report) is that heparin-induced thrombocytopenia (HIT) is a 300-400 million dollar market opportunity and that SmithKline and TXB can conservatively capture 40% of this market after a 1998 launch (as well as 15% of AMI after a year 2000 launch). That's pretty large for a company with a current market cap of about 169 million dollars. But will this all come to pass? Are we sitting on a 12 to 16 dollar company? I sure hope so, but I think alot will depend on how the institutions perceive TXB.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News